CancerDrs

Cervical Cancer clinical trials in Michigan

35 actively recruiting cervical cancer trials at 28 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Trinity Health Medical Center - Canton — Canton, Michigan
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
  • Henry Ford Hospital — Detroit, Michigan
  • Weisberg Cancer Treatment Center — Farmington Hills, Michigan
  • Henry Ford Medical Center-Columbus — Novi, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Michigan:
  • Research Site — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute - Wayne State University — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Henry Ford Hospital — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
  • Henry Ford Hospital — Detroit, Michigan
  • Weisberg Cancer Treatment Center — Farmington Hills, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Michigan:
  • Karmanos Cancer Institute — Detroit, Michigan
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Michigan:
  • Henry Ford Cancer Institute/Henry Ford Health System — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Michigan:
  • Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Michigan:
  • Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit — Detroit, Michigan
  • Profound Research -OMG - TriAtria Cancer Center — Farmington Hills, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Michigan:
  • The Cancer and Hematology Centers ( Site 6912) — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…

Sponsor: Massachusetts General Hospital
NCT ID: NCT05668962
Sites in Michigan:
  • University of Michigan — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, lo…

Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Michigan:
  • BAMF Health — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conduct…

Sponsor: Tanabe Pharma America, Inc.
NCT ID: NCT06943521
Sites in Michigan:
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere …

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT07094685
Sites in Michigan:
  • University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

This phase II trial studies how well personalized neck radiation therapy directed by sentinel lymph node biopsy (SLNB) works in treating patients with oral cavity squamous cell carcinoma (OCSCC). SLNB can be performed as part of standard c…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT07121595
Sites in Michigan:
  • University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Michigan:
  • Karmanos Cancer Institute — Detroit, Michigan
  • Karmanos Cancer Institute — Farmington Hills, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…

Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Michigan:
  • START Midwest Cancer and Hematology Centers of W Michigan — Grand Rapids, Michigan
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in Michigan. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19